Unicycive Therapeutics, Inc. (UNCY) Stock Analysis

Company Overview

Unicycive Therapeutics, Inc. (UNCY) carries a market capitalisation of $106.01M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 21 employees.

The 52-week range on file runs from $3.35 to $8.74. The most recent close on file for UNCY is $3.87, dated October 21, 2026. That is +$0.07 (+1.84%) against the previous close. The latest close sits 15.52% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $26.56M. Earnings per share on a trailing basis come to −1.72.

Across the 4 fiscal years on file, revenue moves from $951.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 2.3.

The trailing one-year total return is −21.66%. Across 5 years the annualized return works out at −31.78%. The reported beta is 1.82. Annualized volatility over the trailing 5 years is 118.89%.

Growth & Income

No dividend is on file for UNCY.

So far in 2026 the total return is −32.93%. The strongest complete calendar year on file is 2023 at +60.74%; the weakest is 2022 at −73.79%. Of the 4 complete calendar years on file, 1 finished higher.